The two policies that matter
Two Google Ads policies get named in every discussion of this category. Only one of them is actually about it.
The first is the healthcare and medicines policy. It opens by saying that “Google Ads is dedicated to following advertising regulations for healthcare and medicine, so ads and destinations are expected to follow appropriate laws and industry standards.” Note the word destinations: it decides more disapprovals than the ad text does. This is the policy a research peptide catalog is read against, and the part that applies is the unapproved substances section below.
The second is the dangerous products or services policy, which says “Google Ads prioritizes safety both online and offline, so you can’t promote products or services that cause damage, harm, or injury in your ads or destinations.” That sentence gets quoted a lot. Read the rest of the page. The categories it names are guns, explosives, weapons, recreational drugs, tobacco, sodium nitrite above a stated concentration, and products subject to a consumer advisory or product recall. Pharmaceuticals and supplements are not on it. If someone tells you this is the policy that stops you advertising, they have not read past the first line.
Getting that right matters for a practical reason: the consequence is different. The unapproved substances page and the dangerous products page both say violations “won’t lead to immediate account suspension without prior warning” and that “a warning will be issued at least 7 days prior to any suspension of your account.” The healthcare and medicines page carries no such line. Two of its sections, unauthorized pharmacies and prescription opioid painkillers, say the opposite, and that split is covered under appeals below.
Which rule you are read under depends on what you sell
The healthcare and medicines policy is not one rule. It is a page of named sections, and which one you are read under depends on what you sell. Three of them decide where most brands in this category sit:
- A prescribing or dispensing service is read under Prescription drug services, and it has to apply before it can run anything.
- Any advertiser using prescription drug terms is read under Restricted drug terms, whatever it sells.
- A research compound catalog is read under Unapproved substances, which is the section below.
The middle one catches people out, because it is not about your product. The Restricted drug terms section says “Google restricts the use of prescription drug terms in ads, landing pages, and keywords.” It then says “Depending on location, you may be able to use these terms for the purpose of promoting prescription drugs.” Read where that reaches. The keyword list and the landing page are both named, not just the ad text. A term you never typed into an ad, sitting in a keyword or on the page the ad points at, is inside the restriction.
Unapproved substances, the sub-policy that applies
Inside the healthcare policy sits the unapproved substances policy. This is the page to read first. It opens: “Google doesn’t allow the promotion of certain products, regardless of any claims of legality:” and then lists them. These items are the ones a peptide brand should read closely, quoted in full:
- “All items on this non-exhaustive list of unapproved pharmaceuticals and supplements”
- “Non-government approved products that are marketed in a way that implies that they’re safe or effective for use in preventing, curing, or treating a particular disease or ailment”
- “Products that have been subject to any government or regulatory action or warning”
- “Products with names that are confusingly similar to an unapproved pharmaceutical or supplement or controlled substance”
Six words in the opener do most of the work: “regardless of any claims of legality”. A product that is legal to sell can still be a product Google will not promote, so an argument about legality is not an argument about the policy. The second item does the rest. It is written about how a product is marketed rather than what it is, which is why two brands selling the same catalog can get different answers.
The “non-exhaustive list” in the first item is a separate page, and its framing matters before anyone treats it as a checklist: “This page lists examples of pharmaceuticals and supplements that Google Ads doesn’t allow as part of the Healthcare and medicines policy. This is not an exhaustive list, and is intended to provide examples of the types of content monitored under the Unapproved substances policy.” The named entries are consumer supplement products. Your compound not appearing there tells you nothing, because the page says so itself.
One thing none of these pages contains: the word peptide. Google has not published a peptide rule. It has published clauses broad enough to cover the category, which someone applies to your account when it comes up for review. The email platforms that allow peptide brands follow the same pattern. Only one vendor names the category outright. The rest rely on pharmaceutical wording. We quote each of those clauses in full on the platform policy tracker.
Certification, and why it does not help this catalog
Somebody will tell you to get certified. The healthcare policy says “some types of healthcare-related content can’t be advertised at all, while others can only be advertised in certain locations by advertisers who have applied and been approved to advertise those products or services using Google Ads.” Read both halves. One category cannot be advertised, another can once you are approved, and certification moves you inside the second only.
What the second contains is named directly: “Google restricts the promotion of services related to the online prescribing, dispensing, and sale of prescription drugs”, and “advertisers must apply to serve ads for prescription drug services.” Those are pharmacies and telemedicine providers. A research compound catalog is not a prescribing or dispensing service, so there is no application for it to file. Certification is a door into the prescription business, not a door around the unapproved substances list.
Location is the other dimension. Most of that page is country-by-country detail, and the requirements differ. One country wants registration with a named national regulator. Another wants accreditation by a certification program. Several ban prescription drug terms in the ad or the landing page. The program has a name. In the Telemedicine entry of the Australia section, Google writes: “Google allows the promotion of telemedicine providers if they are verified by LegitScript’s Healthcare Merchant Certification Program”. The online pharmacies entry above it names the same program. So what it certifies is pharmacies and telemedicine providers, which is why a research catalog has no application to file. If you advertise across borders, the policy that applies is the one for every country you target.
Why compound names in ads get disapproved
Read the list again and the common thread is identity and implication. Two clauses carry this directly: products with names “confusingly similar to an unapproved pharmaceutical or supplement or controlled substance”, and products “subject to any government or regulatory action or warning”.
The second clause is the one operators underrate, because it needs nothing from your own business. A compound named in regulatory action is in scope by the words of the policy, whoever sells it. The 2026 FDA warning letters are public and they are about this category. A reviewer does not need a theory about your catalog when a federal agency has published one.
None of that means there is a wording trick waiting for you. Some of these clauses turn on the product's identity and some on what the marketing implies. A rename changes neither. A renamed product with the same page behind it is the same submission. The useful read is narrower: a disapproval here is usually telling you something true about the copy, and copy is what those letters turned on.
Landing pages count too
Every policy page quoted above puts the destination in scope. The healthcare policy expects “ads and destinations” to follow the law and industry standards. The dangerous products policy uses the phrase “in your ads or destinations”. And the unapproved substances page lists, among the ways to fix a disapproval, that “you can also choose a new landing page for your ad that complies with this policy.”
The review can reach further than the page you linked. The unauthorized pharmacies section of the healthcare policy says this, about that section and not the whole page: “In determining whether an advertiser or destination is violating this policy, Google may review information from multiple sources including your ad, website, accounts, and third-party sources.” That is a review of your site and your accounts, not a scan of thirty characters of ad text.
So a clean ad pointing at a catalog page is one submission, and the catalog page is most of it. Tidying headlines while the destination stays the same is not a change the review will notice.
Search ads are also not the only surface. A product feed is reviewed separately, under the Shopping ads and listings policies, and those policies name this category in the same words the ads policy does. “Google restricts the listing of healthcare-related content such as the following:” and one of the four items under it is “Unapproved pharmaceuticals and supplements”. The sentence to read twice is the one about where it applies: “The restrictions that apply to this content may vary depending on the product you’re listing and the countries that you’re targeting. Some content, such as unapproved pharmaceutical supplements, may not be listed anywhere.”
Enforcement there is its own track too. On action, Google writes: “This may include disapproving violating Shopping ads and listings so they don’t serve, temporarily capping impressions for some accounts flagged by Google AI, and suspending accounts for repeat or egregious violations.” For a catalog brand that is usually where the stop happens, and a clean Search ad does not change it.
The way back is its own track as well, and there are two of them. The same page says “If one of your Shopping listings is disapproved, you can fix that listing or appeal the decision.” It then adds “You can also appeal an account suspension decision”. A listing appeal and an account appeal are different requests, and both are filed from inside Merchant Center. Filing the first one does nothing about the second.
What peptide brands do instead
The channels that work here are the ones where nobody reviews your copy before a buyer sees it. There are three.
- Organic search. The questions your buyers type are answerable in public, and a page that answers one keeps earning after it is written. Nothing about it is submitted for approval.
- Email to a list you own. The asset is the list and the sending setup behind it. No platform decides each morning whether your message runs.
- Owned content that explains the category. Policy explainers, compliance guides, sourcing and testing detail. This is what gets cited, and what AI assistants quote back.
That is the reason this site exists. Amino Engine is an email marketing platform for peptide brands. Mail sends from your own domain, on servers and IP addresses we run. No outside email provider sits above your account. There are 82 ready-made flows, a WooCommerce plugin today, and CSV import from Klaviyo or Brevo with unsubscribes and bounces carrying over. See pricing.
On paid specifically, Meta's rules for this category are written differently and are reviewed differently, so they need their own page. Ours is at peptide ads, and the wider federal, state and platform picture is in our 2026 compliance landscape.
Appeals, and what a disapproval actually costs
A disapproval under the unapproved substances policy is not an account suspension. The page says violations “won’t lead to immediate account suspension without prior warning” and that “a warning will be issued at least 7 days prior to any suspension of your account.” It lists two remedies, editing the ad so it complies and choosing a different landing page, then: “If you believe there’s been an error and that you haven’t violated Google Ads policies, appeal the policy decision directly from your Google Ads account to request a review. If the review determines that your ads are compliant, they can run again.”
The hard line sits elsewhere. Google’s account suspensions overview defines an egregious violation as “a violation so serious that it is unlawful or poses significant harm to our users or our digital advertising ecosystem”, and says that for one of those “we will suspend your Google Ads accounts immediately without prior warning. You will not be allowed to advertise with us again.” The same page publishes which policies count, and “promotion of unauthorized pharmacies” is on that list while the unapproved substances policy is not. For repeat violations of the policies that are not on that list, Google says the warning “will be sent at least 7 days before a suspension action.”
One more item on that list turns a survivable disapproval into a permanent one: circumventing systems. That policy says Google “doesn’t allow advertisers to attempt to trick or circumvent our ad review processes with their ads, content, or destinations”, and it names what it counts: “bypassing enforcement mechanisms and detection by creating variations of ads, domains or content that have been disapproved for this or any Google Ads policy”, “creating new websites or accounts to show ads that are similar to ones that were already disapproved”, and “after a previous suspension decision, attempting to use the Google Ads system again by creating new accounts to re-enter the system”. Cloaking sits here as well. The consequence is the egregious one: accounts “will be suspended upon detection and without prior warning”.
So the two routes out of a disapproval are not symmetrical. Fixing the copy or the destination and appealing is the route the policy offers you, with a 7-day warning behind it. Respelling a compound, moving the catalog to a second domain or opening a fresh account is the other route. That one is on the list that suspends on detection and bars you for good. The first is slower to accept and the only one with a future.
In the order the quoted clauses put them, that is five steps:
- Check the destination before the ad text. Both are named in the policy, and the destination is the larger half of the submission.
- Remove the term the policy names rather than respelling it. A variation of something already disapproved is on the circumventing list.
- Edit the ad so it complies, which is the first remedy the page offers, and let it be re-reviewed.
- Appeal once and wait. Google asks for one appeal at a time.
- Never open a second account or a second domain for the same catalog. That is the route that suspends on detection.
One procedural note from the account suspensions overview: “If you file too many appeals for the same account suspension, we may not process them to ensure the overall stability of our systems operations. Submitting one appeal at a time ensures timely response and review.” File one, wait for it, keep it accurate.
All seven pages quoted here were read on 8 October 2026. Google has reworded them before and will again, so check the live page before you spend. The clause your account is judged against is the one published that day, not the one in a blog post.
This is general information, not legal advice.